You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Paraproteinemias

Showing 51 - 75 of 95
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early

Completed
  • Plasma Cell Dyscrasia
  • Monoclonal Gammopathy
    • Boston, Massachusetts
      Tufts Medical Center
    May 7, 2020

    Gene Expression Profile of Bone Marrow Plasma Cells From MGUS

    Terminated
    • Monoclonal Gammopathy of Undetermined Significance
    • Smoldering Myeloma
    • Genetic study of DNA copies
    • Rennes, Bretagne, France
    • +26 more
    Apr 13, 2021

    Unravel MGUS (Monoclonal Gammopathy of Unknown Significance)

    Active, not recruiting
    • Monoclonal Gammopathy of Unknown Significance
    • Blood sample taken
    • +2 more
    • Reading, Berkshire, United Kingdom
    • +8 more
    Sep 1, 2020

    Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance Trial (Fluciclatide)

    Withdrawn
    • Multiple Myeloma
    • +2 more
    • (no location specified)
    Dec 13, 2019

    Sleep Apnea in Patients With MGUS and MM

    Recruiting
    • Multiple Myeloma
    • Monoclonal Gammopathy of Undetermined Significance
    • Bone Marrow Aspirate and Biopsy
    • Iowa City, Iowa
      University of Iowa
    Oct 1, 2019

    Myelodysplastic Disorders, Leukemia, Multiple Myeloma Trial in Houston (FLUDARABINE, CAMPATH 1H, FK50)

    Completed
    • Myelodysplastic Disorders
    • +4 more
    • Houston, Texas
    • +1 more
    Jan 15, 2020

    Monoclonal Gammopathy of Renal Significance Trial in Buenos Aires

    Unknown status
    • Monoclonal Gammopathy of Renal Significance
      • Buenos Aires, Argentina
        Academia Nacional de Medicina
      Feb 23, 2019

      AL Amyloidosis Trial in Worldwide (CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen)

      Recruiting
      • AL Amyloidosis
      • Phoenix, Arizona
      • +101 more
      Aug 4, 2022

      Elranatamab, Myeloma, Multiple Myeloma Trial in China (Elranatamab)

      Recruiting
      • Elranatamab
      • +10 more
      • Fuzhou, Fujian, China
      • +18 more
      Jan 18, 2023

      Waldenstrom Macroglobulinemia Trial in New York (Epratuzumab (hLL2- anti-CD22 humanized antibody))

      Terminated
      • Waldenstrom Macroglobulinemia
      • Epratuzumab (hLL2- anti-CD22 humanized antibody)
      • New York, New York
      • +1 more
      Aug 12, 2021

      Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in

      Active, not recruiting
      • Accelerated Phase Chronic Myelogenous Leukemia
      • +125 more
      • tetanus-CMV fusion peptide vaccine
      • laboratory biomarker analysis
      • Duarte, California
        City of Hope Medical Center
      Feb 28, 2022

      Pancreatic Cancer, Thyroid Cancer, Lung Cancer Trial in United States

      Recruiting
      • Pancreatic Cancer
      • +49 more
        • Colorado Springs, Colorado
        • +80 more
        Feb 22, 2022

        Multiple Myeloma Trial in Germany (Isatuximab, Lenalidomide, Bortezomib)

        Recruiting
        • Multiple Myeloma
        • Aachen, Germany
        • +29 more
        Apr 4, 2023

        Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,

        Recruiting
        • Waldenstrom Macroglobulinemia
        • +8 more
        • Iopofosine I 131 single dose
        • +2 more
        • Redlands, California
        • +42 more
        Dec 30, 2022

        Chronic Lymphocytic Leukemia, Fatigue, Fever Trial in Houston (Lenalidomide, Ofatumumab)

        Completed
        Has Results
        • Chronic Lymphocytic Leukemia
        • +9 more
        • Houston, Texas
          M D Anderson Cancer Center
        Apr 16, 2019

        Neuropathy, Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS) Trial in Lebanon (Lenalidomide)

        Terminated
        Has Results
        • Neuropathy
        • Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)
        • Lebanon, New Hampshire
          Dartmouth-Hitchcock Medical Center
        Sep 7, 2018

        Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy Trial in Boston (Intravenous immunoglobulin, 0.9% Sodium Chloride)

        Active, not recruiting
        • Small Fiber Neuropathy
        • Idiopathic Peripheral Neuropathy
        • Intravenous immunoglobulin
        • 0.9% Sodium Chloride
        • Boston, Massachusetts
          Beth Israel Deaconness Medical Center
        Apr 16, 2021

        Comprehensive Frailty Assessment

        Completed
        • Myeloma, Multiple
        • +2 more
          • Columbus, Ohio
            The Ohio State University Hospital East
          Feb 27, 2018

          Multiple Myeloma, Tumors, Plasma Cells Trial (Lenalidomide)

          Withdrawn
          • Multiple Myeloma
          • +6 more
          • (no location specified)
          Apr 9, 2018

          Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma Trial in Lebanon (GM-CSF, IL-2)

          Completed
          • Non-Hodgkin's Lymphoma
          • +4 more
          • Lebanon, New Hampshire
            Dartmouth-Hitchcock Medical Center
          Apr 23, 2018

          Multiple Myeloma Trial in Boston, New York, Milwaukee (AT7519M, Bortezomib)

          Completed
          • Multiple Myeloma
          • Boston, Massachusetts
          • +4 more
          Jan 13, 2020

          Multiple Myeloma Trial (Vorinostat, bortezomib, to vorinostat)

          Completed
          Has Results
          • Multiple Myeloma
          • (no location specified)
          Apr 29, 2021

          Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging

          Withdrawn
          • Amyloidosis
          • +2 more
          • Amyloidosis
          • Cardiac Amyloidosis
          • Cincinnati, Ohio
            University of Cincinnati
          Oct 24, 2017

          Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance Trial run by the NCI (18-NaF

          Completed
          Has Results
          • Multiple Myeloma
          • +2 more
          • 18-NaF PET
          • +2 more
          • Bethesda, Maryland
            National Institutes of Health Clinical Center, 9000 Rockville Pi
          Jul 7, 2017

          Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma Trial in Boston (Relaxation Response Resiliency

          Completed
          • Monoclonal Gammopathy of Undetermined Significance
          • Smoldering Multiple Myeloma
          • Relaxation Response Resiliency Program (3RP)
          • Boston, Massachusetts
          • +2 more
          Mar 15, 2017